Sun Pharma Q1 net up 43% to Rs 2,061 crore on specialty sales, India biz

Gross sales up 10.1% YoY to Rs 10,644 cr; EBITDA at Rs 2,884.4 cr, with a margin of 26.8%

Sun Pharma
Premium

The company said that excluding sales of Covid-19 products, the overall sales are up by about 14 per cent.

Sohini Das Mumbai
India’s largest drug maker Sun Pharmaceutical Industries has posted a 43 per cent rise in net profit for the first quarter of the current fiscal year, to Rs 2,061 crore, beating street estimates, riding on robust sales across India, US and emerging markets. The firm’s gross sales were up 10.1 per cent year-on-year (YoY) to Rs 10,644 crore during the quarter, from Rs 9,719 crore a year ago.

Excluding the exceptional items of Q1 last year, the adjusted net profit was up 4.1 per cent.

EBITDA for the quarter came in at Rs 2,884.4 crore (including other operating revenues), and

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 29 2022 | 4:33 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com